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The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immu-
nopathology of psoriasis, hallmarks of which involve the activation of both resident 
and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research 
demonstrates a role for IL-36γ in both myeloid activation and angiogenesis. We show 
that IL-36γ induces the production of psoriasis-associated cytokines from macrophages 
(IL-23 and TNFα) and that this response is enhanced in macrophages from psoriasis 
patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family 
cytokines such as IL-1α. IL-36γ was also demonstrated to induce endothelial tube for-
mation and branching, in a VEGF-A-dependent manner. Furthermore, IL-36γ-stimulated 
macrophages potently activated endothelial cells and led to increased adherence of 
monocytes, effects that were markedly more pronounced for psoriatic macrophages. 
Interestingly, regardless of stimulus, psoriasis monocytes showed increased adherence 
to both the stimulated and unstimulated endothelium when compared with monocytes 
from healthy individuals. Collectively, these findings show that IL-36γ has the potential 
to enhance endothelium directed leucocyte infiltration into the skin and strengthen the 
IL-23/IL-17 pathway adding to the growing evidence of pathogenetic roles for IL-36γ in 
psoriatic responses. Our findings also point to a cellular response, which could poten-
tially explain cardiovascular comorbidities in psoriasis in the form of endothelial activation 
and increased monocyte adherence.
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inTrODUcTiOn
Psoriasis is an immune mediated inflammatory disease which affects 2–3% of the world’s population 
(1). Psoriatic lesions manifest as hyperkeratotic plaques, dermo-epidermal inflammation, and aber-
rant blood vessel formation caused by the complex interplay between tissue resident cells, dendritic 
cells, macrophages, and T  cells and resultant enhanced expression of the IL-23–Th17/Th22 and 
IL-12–IFNγ/TNFα pathways (2).
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IL-36α, IL-36β, and IL-36γ are members of the IL-1 family 
of cytokines that signal through a common receptor composed 
of IL-36 receptor (IL-36R) and IL-1R/AcP to activate NF-κB 
and MAPKs, such as p38 and JNK, and promote inflammatory 
responses.
IL-36α, IL-36β, and IL-36γ are members of the wider IL-1 
family of cytokines. These cytokines mediate inflammatory 
events through the IL-36R and activate NF-κB and MAPKs, such 
as p38 and JNK in susceptible cells. The significance of IL-36γ 
for psoriatic inflammation is increasingly being recognised (3–6). 
IL-36 cytokines, in particular IL-36γ is dramatically upregulated 
in lesional psoriasis when compared with healthy controls (5). As 
well as acting as a psoriatic biomarker, loss-of-function mutations 
in the IL-36R antagonist (IL-36RA) in multiple cohorts of general-
ised pustular psoriasis (GPP) patients provide evidence that IL-36 
plays a causative role in the pathology of psoriasis (7–9). IL-36 has 
recently also been implicated in other skin inflammatory diseases 
including acne and hidradenitis suppurativa, and allergic contact 
dermatitis (10, 11). IL-36γ, which is highly expressed by epithelial 
cells, is thought to be released in the context of cell damage or via 
non-conventional secretory pathways (12–14). Following release, 
it has been shown that IL-36γ is processed into its bioactive form 
by cathepsin S and results in the subsequent stimulation of sur-
rounding tissues (15). IL-36R-mediated signal transduction has 
been shown to induce the release of pro-inflammatory cytokines 
(e.g., IL-8, TNFα, and IL-6), upregulate antimicrobial peptides 
and proliferative mediators such as defensins and HB-EGF, as 
well as T cell attracting or polarising cytokines such as CCL20 
and IL-12, respectively (16–19).
Angiogenesis is the formation of new blood vessels from the 
preexisting vasculature and is a hallmark of psoriasis lesions 
(20). Microvascular changes within psoriasis lesions include 
pronounced dilation, increased permeability and endothelial cell 
proliferation. Immature permeable blood vessels may enhance 
dermal inflammation through immune cell recruitment (21, 
22). A recent study confirmed a positive correlation between 
hypervascularisation and disease severity (23). Excessive 
capillary-venular dilatation precedes development of psoriatic 
inflammation, and resolution of these vascular changes is associ-
ated with remission of psoriasis lesions (24). VEGF-A is thought 
to be the driving force behind angiogenesis observed in psoriatic 
lesions. Mice that overexpress VEGF-A show an inflammatory 
response that histologically resembles psoriasis (25, 26). The 
VEGFA gene is located on chromosome 6 at 6p21, close to PSORS 
1, which is a known chromosomal locus for psoriasis susceptibil-
ity (27, 28). The +405 CC VEGFA genotype, also known as the 
“high VEGF-A-producing genotype,” is associated with early 
onset psoriasis, whereas the “low VEGF-A-producing genotype” 
has no association with psoriasis (29–31). This suggests that the 
pro-angiogenic potential of an individual may influence disease 
progression.
Treatment of human psoriasis with biologics has unequivo-
cally shown that activation of the IL-23/IL-17 pathway is key for 
clinical symptom development (32). IL-23 induces and maintains 
the differentiation of IL-17- and IL-22-producing lymphocytes, 
which serve as the primary source of IL-17 and IL-22, both of 
which orchestrate epidermal hyperplasia and tissue inflammation 
in psoriasis (2). In murine induced psoriasis models, infiltrating 
macrophages, monocytes, and monocyte-derived dendritic cells 
and their subsequent T cell activating cytokines such as IL-23 have 
been shown to drive inflammation (33–37). A mechanistic link 
between IL-36 and the IL-23/IL-17 axis is becoming increasingly 
clear (6, 38–40). Work on other inflammatory skin diseases has 
also highlighted a correlation between IL-36 and IL-17 (41, 42).
Whilst previous reports have shown that IL-36γ induces 
inflammatory mediators from macrophages, little is known about 
its ability to induce psoriasis relevant cytokines such as TNFα 
and IL-23 (16). The ability of IL-36γ to induce such inflamma-
tory mediators from infiltrating macrophages could escalate the 
inflammatory cascade by activating surrounding fibroblasts, 
endothelial cells (18), and keratinocytes and ultimately lead to 
further immune cell recruitment. In recent studies, GPP patients 
with DITRA (Deficiency of IL-36R Antagonist) showed significant 
disease improvement after receiving monocyte apheresis therapy, 
highlighting the potential importance of an IL-36-macrophage 
axis in the pathology of psoriasis (43, 44).
In this study, we highlight the role of IL-36γ in both mac-
rophage and vascular activation in the context of psoriatic 
lesions. Our data demonstrate that IL-36γ induces the secretion 
of a key driver of psoriasis, IL-23, by macrophages and that this 
induction is enhanced in macrophages of psoriasis patients. 
IL-36γ also induces angiogenesis and branching of endothelial 
cells in a VEGF-A-dependent manner. Supernatant from IL-36γ 
treated macrophages potently activate endothelial cells and 
increased ICAM-1 expression. Psoriasis monocytes show an 
increased adhesion to both stimulated and untreated endothelial 
cells. Overall, the presented findings add to the growing body 
of evidence for IL-36γ as highly relevant molecule in psoriasis 
immunopathology.
MaTerials anD MeThODs
cell isolations and cell culture
Blood was collected in sodium citrate tubes. PBMCs were 
separated using Lymphoprep density gradient centrifugation. 
Monocytes were isolated from PBMCs using magnetic separa-
tion CD14+ beads (Miltenyi Biotech) using the Dynal MPC 
column (Invitrogen, CA, USA). Monocytes were resuspended 
in RPMI (ThermoFisher Scientific, MA, USA) containing 10% 
FCS and penicillin/streptomycin (100 U/100  mg/ml; both Life 
Technologies, Carlsbad, CA, USA). CD14+ purity was tested by 
FACs analysis with mouse antihuman CD14 FITC conjugated 
or mouse IgG isotype control (both 1:100; both ImmunoTools, 
Friesoythe, Germany). Purity for healthy patients was >90% 
(Figure S2 in Supplementary Material). Umbilical cords were 
supplied by Bradford Royal Infirmary under the approval and 
processing of Ethical Tissue Bradford. Human umbilical vein 
endothelial cells (HUVECs) were isolated from umbilical cords in 
a previously described method (45). Monocytes were seeded onto 
plates (dependent on application) in RPMI overnight to generate 
day 1 macrophages.
Table 1 | Patient demographics.
Diagnosis age gender Disease duration (years) Psa Pasi current systemic treatment
Plaque psoriasis 48 Female 42 Yes Minimal disease activity Secukinumab
Plaque psoriasis 38 Male 10 No 14.4 None
Plaque psoriasis 43 Female Unknown No Minimal disease activity Ustekinumab
Plaque psoriasis 55 Male 10 No Minimal disease activity None
Plaque psoriasis 41 Male 10 Yes Minimal disease activity Adalimumab
Plaque psoriasis 24 Female 13 No 5.1 None
Plaque psoriasis 52 Male 13 No 6 Ustekinumab
Plaque psoriasis 48 Male 10 No 8.1 None
Plaque psoriasis 29 Female 22 No 7.7 None
Plaque psoriasis 41 Female 28 Yes 1.2 Ustekinumab
Plaque psoriasis 35 Male 15 No 4 Ustekinumab
Plaque psoriasis 37 Male 10 No 8 None
Plaque psoriasis 48 Female 30 Yes 13 None
Pustular palmoplantar and plaque 
psoriasis
70 Female Unknown No Minimal disease activity Ustekinumab
PsA, psoriatic arthritis; PASI, Psoriasis Area and Severity Index.
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Macrophage Purity and il-36r 
confirmation
Isolated macrophages were seeded onto coverslips overnight. 
Cells were washed in PBS and fixed in 4% formaldehyde for 
20 min. Cells were then blocked for 1 h in 5% BSA in PBS. Cells 
were incubated overnight with rabbit anti-human IL-36R 1:500 
(Novus Biologics, Littleton, CO, USA) or rabbit IgG isotype 
control (1:500; Abcam, Cambridge, UK). Cells were then washed 
with PBS and incubated with donkey anti-rabbit Alexa 594 con-
jugated and mouse anti-human CD14 FITC conjugated or mouse 
IgG isotype control (both 1:100; both ImmunoTools, Friesoythe, 
Germany). Cells were visualised using the EVOS XL microscope 
(Thermo Fisher Scientific).
Patient Demographics
Details on patients who gave blood for the study are listed below in 
(Table 1). All patients included are under care in the dermatology 
department and have a diagnosis of plaque psoriasis; one patient 
presented mainly with palmoplantar pustular psoriasis at the time 
point blood was taken. Patients receiving conventional systemic 
treatment known to change the biological response of leucocytes, 
in particular methotrexate, cyclosporine A, or leflunomide were 
excluded from the study. For this experimental setup, where cells 
were isolated involving multiple washing steps, cell culture and ex 
vivo stimulation, biologics treatment was not an exclusion crite-
ria. We carefully checked the dataset, and there was no tendency 
for a difference in our outcome measured between cells derived 
from patients with or without biologics treatment.
As for the healthy controls, none were known to suffer from 
psoriasis, eczema or any active inflammatory disease under 
systemic treatment. Healthy controls were matched regarding 
gender distribution; the age range was between 28 and 52.
Macrophage cytokine stimulation
Monocytes were seeded at 1 ×  105 in 96-well plates (Greiner 
Bio-One, Stonehouse, UK) in RPMI overnight to generate day 
1 macrophages. Where relevant, macrophages were primed for 
24  h with IFNγ 20  ng/ml. Macrophages were stimulated with 
IL-36γ protein, which was generated as previously described 
(15, 46), IL-17, TNFα, and IL-1α (PeproTech, Rocky Hill, NJ, 
USA). Following 48  h stimulation, supernatant was stored at 
−80°C. Concentrations of IL-23 and TNFα were measured using 
ELISA kits from eBioscience/ThermoFisher (Waltham, MA, 
USA). ELISAs were carried out according to the manufacturer’s 
protocols. Reproducibility of the supernatants was confirmed by 
triplicate testing, with <10% error.
Tubulogenesis assay
Primary human foreskin fibroblasts (PromoCell, Heidelberg, 
Germany) were cultured in 48-well plates in complete DMEM 
[containing 10% (v/v) FCS, 1% (v/v) non-essential amino acids 
and 1% (v/v) sodium pyruvate] until confluent. 6,500 HUVECs 
were seeded onto the fibroblasts monolayer in a 1 ml 1:1 mixture 
of complete DMEM and ECGM (PromoCell). Cells were left to 
acclimatise for 24 h. Media were aspirated and replaced with fresh 
ECGM ± growth factors (VEGF-A, 10 ng/ml) or IL-36 (50 ng/
ml) or inhibitors (IL-36RA, 50 ng/ml), Sutent (Sigma, 1 nM) or 
anti-VEGF-A neutralising antibody (R&D Systems, 50 or 100 ng/
ml) as indicated; media were replaced every 2–3 days for 9 days. 
Cocultures were fixed in 200 µl 10% (v/v) formalin for 20 min and 
blocked in 5% (w/v) BSA for 30 min at RT. Cocultures were then 
incubated with 1  µg/ml mouse anti-human PECAM-1 (CD31) 
(Santa Cruz, Dallas, TX, USA) overnight at 4°C. Cells were 
washed three times with PBS before incubation with anti-mouse 
Alexa Fluor 594 conjugate (Invitrogen) for 3 h at RT. Wells were 
washed three times with PBS. Endothelial tubules were visualised 
via immunofluorescence microscopy using an EVOS-fl inverted 
digital microscope (Thermo Fisher Scientific). Three random 
fields were imaged per well. Total tubule length and number 
of branch points were quantified from each photographic field 
using the open source software AngioQuant (www.cs.tut.fi/sgn/
csb/angioquant) and values were averaged. For a more detailed 
method, see Ref. (47).
VegF-a induction Quantification by 
immunoblot and elisa
Endothelial or fibroblast cells were seeded into 6-well plates 
and cultured in ECGM or complete DMEM until ~80% 
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confluent. Cells were then washed twice with PBS and starved 
in MCDB131  +  0.2% (w/v) BSA for 2  h before stimulation 
with IL-36 (50 ng/ml) for 24 h. Cells were then washed twice 
with ice-cold PBS and lysed in 2% (w/v) SDS, TBS, 1  mM 
PMSF and protease inhibitor cocktail (Sigma-Aldrich). Protein 
concentration was determined using the bicinchoninic acid 
assay (ThermoFisher). 20  µg of protein lysate was subjected 
to SDS-PAGE before transfer onto nitrocellulose membrane 
and analysis via immunoblotting using antibodies against 
VEGF-A, VEGFR1, and VEGFR2 (R&D Systems). For a detailed 
immunoblot protocol, see Ref. (48). The relative expression of 
the non-stimulated control was set to 1, and all other results 
expressed as a ratio of this. To measure VEGF-A secretion from 
both cell types, the supernatant was tested using VEGF-A ELISA 
kit (eBioscience/ThermoFisher).
Macrophage supernatant-endothelial 
activation assay
Following 48 h stimulation, supernatant was removed and stored 
at −80°C. HUVEC was cultured on black TC grade fluores-
cence plates (PerkinElmer, Waltham, MA, USA), in PromoCell 
endothelial cell media containing penicillin/streptomycin 
(100  U/100  mg/ml) (Life Technologies, Carlsbad, CA, USA). 
Supernatant was cultured with HUVEC at ratio of 1:10 for 24 h. 
Recombinant IL-36γ was added to control wells to serve as a 
blank. After 24 h, the cells were fixed for 15 min with 4% for-
maldehyde in PBS. Mouse anti-human ICAM-1 FITC or mouse 
IgG isotype control was added (1:500) (BioLegend, San Diego, 
CA, USA). The fluorescence intensity of each well was measured 
using the Promega GloMax plate reader (Madison, WI, USA). For 
immunocytochemistry, the cells were visualised using the EVOS 
XL microscope.
Monocyte adherence assays
Monolayers of HUVEC were grown to confluence in 24-well 
plates (Greiner Bio-One). HUVECs were stimulated with mac-
rophage supernatant as above, or with TNFα (10 ng/ml) for 24 h 
and then suspended in fresh media before experiments. 1 × 105 
monocytes were added per chamber for 30 min. After 30 min, 
non-adherent cells were washed away, and the cells were fixed 
using 4% formaldehyde in PBS and blocked in 5% BSA in PBS 
for 1 h. The cells were the stained with mouse anti-human CD14 
FITC conjugated or mouse IgG isotype control (both 1:100) 
(both ImmunoTools). The cells were visualised using the EVOS 
XL microscope, and the number of adhered cells counted using 
ImageJ software.
statistical analysis
This was performed using a one-way analysis of variance 
(ANOVA) followed by Tukey’s post  hoc test, two-way ANOVA 
followed by Bonferroni multiple comparison or single unpaired 
t-test using GraphPad Prism software (La Jolla, CA, USA). 
Significant differences between control and test groups were eval-
uated with p values less than *p < 0.05, **p < 0.01, ***p < 0.001, 
and ****p < 0.0001 indicated on the graphs. Error bars represent 
the SEM.
resUlTs
il-36γ induces increased il-23 and TnFα 
from Psoriasis Macrophages
Psoriasis is driven by aberrant type-3 immune responses, charac-
terised by high levels of IL-17 and IL-22 (32, 49). A key inducer 
of type-3 responses is IL-23, which is expressed by antigen-pre-
senting cells including macrophages upon stimulation with TLRs 
agonists such as LPS and flagellin (50, 51). IL-36γ is an abundant 
and prominent mediator in skin psoriasis, and we were interested 
in its ability to induce IL-23 expression by macrophages.
In support of previous mRNA data (52) IL-36R protein was 
found to be expressed by blood derived CD14+ monocyte/mac-
rophages (Figure 1A) (n = 3, healthy). To assess the functional 
significance of IL-36γ interactions with macrophages, IL-36γ 
stimulation was performed for 48  h before analysis of TNFα 
and IL-23 secretion via ELISA (Figure  1B). As macrophages 
are known to be sensitive to LPS stimulation, boiled IL-36γ was 
included as a control for potential endotoxin contamination of 
the protein preparation. TNFα induction was measured at 24 and 
48 h (Figure S1 in Supplementary Material). Differences between 
treatment groups became more apparent when more time was 
allowed for the secreted mediator to accumulate. Both 10 and 
50  ng/ml IL-36γ induced a significant increase in IL-23 secre-
tion when compared with unstimulated cells, which was further 
amplified when the macrophages were primed with IFNγ 20 ng/
ml. For both doses of IL-36γ, macrophages from psoriatic donors 
secreted significantly more IL-23 compared with cells from 
healthy individuals. Other psoriasis relevant mediators such as 
IL-17, TNFα, and IL-1 did not induce a significant increase in 
IL-23 secretion, regardless of IFNγ priming. IL-36γ also induced 
significant TNFα secretion from macrophages, as did both IL-1 
and IL-17 when compared with untreated controls. However, fol-
lowing IFNγ priming, IL-36γ induced secretion exceeded both 
IL-1 and IL-17.
il-36-stimulated endothelial cell 
Tubulogenesis
IL-36’s relationship with angiogenesis in the context of inflam-
mation is presently unknown. To close this knowledge gap, 
we investigated the role of IL-36 in blood vessel formation. 
Endothelial cell tubulogenesis was assessed using an endothelial-
fibroblast coculture assay. Here, human endothelial cells were 
cocultured on a monolayer of primary human fibroblasts, before 
IL-36 or VEGF-A (positive control) stimulation, fixation, and 
visualisation of PECAM-1 positive endothelial cells (Figure 2A). 
Quantification revealed that both IL-36γ and IL-36α (50  ng/
ml) stimulation produced a significant increase in both tubule 
length (Figure 2B) and branch point number (Figure 2C). Such 
effects were dependent on IL-36/IL-36R interactions, as treat-
ment with an IL-36RA impaired IL-36-stimulated tubulogenesis 
(Figures 2A–C). Endothelial cell tubulogenesis was also enhanced 
in response to VEGF-A (10  ng/ml; Figures  2A,D,E); however, 
as expected, this was unaffected by co-treatment with IL-36RA 
(Figures 2A,D,E). Thus, these data show that IL-36R-mediated 
signal transduction promotes endothelial cell tubulogenesis.
FigUre 1 | (a) IL-36 receptor (IL-36R) (red) on macrophages; CD14+ (green) (magnification 20×). (b) Following 48 h stimulation with IL-36γ, IL-1α, IL-17A, TNFα, 
and IFNγ (24 h priming), supernatant was analysed by ELISA for TNFα and IL-23. Unpaired t-test *p < 0.05, **p < 0.01 psoriasis versus healthy (sample size: 
psoriasis = 9, healthy = 9, and boiled control n = 3).
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il-36-stimulated endothelial cell 
Tubulogenesis is VegF-a Dependent
VEGF-A is a strong promoter of angiogenesis (53) and endothelial 
cell tube formation (Figure  2). Pro-angiogenic molecules such 
as IL-6 have been shown to induce the expression and secretion 
of VEGF-A; therefore, one possibility was that IL-36-mediated 
endothelial cell tube formation could be dependent on increased 
VEGF-A signalling. To test this, human endothelial cells were 
cocultured on a bed of primary human fibroblasts and stimu-
lated with IL-36 or VEGF-A (positive control) in the presence or 
absence of an anti-VEGF-A neutralising antibody or the VEGFR 
inhibitor, Sutent (Figure 3A). Here, quantification revealed that 
IL-36-stimulated (50  ng/ml) endothelial cell tubulogenesis was 
significantly impaired in response to either the anti-VEGF-A 
neutralising antibody (50 and 100  ng/µl) or Sutent (1  nM; 
Figures  3A–C). As expected, VEGF-A-stimulated endothelial 
cell tubulogeneis was also impaired in response to either the 
anti-VEGF-A neutralising antibody or Sutent (Figures 3A,D,E). 
Therefore, these data show that IL-36-stimulated endothelial 
cell tube formation is dependent on VEGF-A-mediated signal 
transduction.
il-36 stimulation Upregulates VegF-a 
Protein levels in Fibroblast cells
After concluding IL-36-induced angiogenesis is depend-
ent on VEGF-A-mediated signal transduction (Figure  3), 
we assessed the effect of IL-36 stimulation on the protein 
levels of VEGF-A and its receptors VEGFR1 and VEGFR2. 
Here, endothelial or fibroblast cells were serum-starved 
before IL-36 stimulation (50  ng/ml; 24  h); cells were then 
lysed and subjected to immunoblotting (Figure  3A). Here, 
IL-36 stimulation significantly increased VEGF-A protein 
levels (~2-fold) in primary fibroblasts (Figures  4A,B), but 
not in endothelial cells (Figures 4A,B). IL-36 also induced 
significant VEGF secretion by fibroblasts, but not endothe-
lial cells, as detected by ELISA (Figure 4C). However, IL-36 
FigUre 2 | IL-36 stimulates endothelial cell tubulogenesis. (a) Human umbilical vein endothelial cells were cocultured on a bed of primary human fibroblasts for 
9 days and stimulated with either IL-36 (50 ng/ml) or VEGF-A (10 ng/ml). Cocultures were then fixed and stained for PECAM-1, before visualisation using 
immunofluorescence microscopy. (b,c) Quantification of (b) total tubule length or (c) number of branches upon IL-36 stimulation. (D,e) Quantification of (D) total 
tubule length or (e) number of branches upon VEGF-A stimulation. Scale bar represents 1,000 µm (n = 3). One-way analysis of variance was performed (*p < 0.05, 
**p < 0.01, and ***p < 0.001).
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FigUre 3 | IL-36-stimulated endothelial cell tubulogenesis is VEGF-A dependent. (a) Human umbilical vein endothelial cells were cocultured on a bed of primary 
human fibroblasts for 9 days and stimulated with either IL-36 (50 ng/ml) or VEGF-A (10 ng/ml) ± 50 ng/ml anti-VEGF-A antibody, 100 ng/ml anti-VEGF-A antibody, 
or 1 nM Sutent. Cocultures were then fixed and stained for PECAM-1, before visualisation using immunofluorescence microscopy. (b,c) Quantification of (b) total 
tubule length or (c) number of branches upon IL-36 stimulation. (D,e) Quantification of (D) total tubule length or (e) number of branches upon VEGF-A stimulation. 
Scale bar represents 1,000 µm (n = 3). Two-way analysis of variance (ANOVA) (c,D) and one-way ANOVA (D,e) were applied (*p < 0.05, **p < 0.01, and 
***p < 0.001).
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FigUre 4 | IL-36 stimulates VEGF-A expression and secretion by primary human fibroblasts. (a) Human umbilical vein endothelial cells or foreskin-derived 
fibroblasts were stimulated with IL-36 (50 ng/ml) for 24 h, before cell lysis. Endothelial cell or fibroblast lysates were processed for detection of VEGF-A protein levels 
via immunoblot analysis. (b) Quantification of VEGF-A protein levels upon IL-36 stimulation by 2D-densitometry (n = 3). (c) The supernatant from both the 
stimulated cell types was also tested for VEGF-A protein concentration. Two-way analysis of variance was performed (*p < 0.05).
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stimulation had no significant effect on VEGFR1 or VEGFR2 
protein levels in either cell type (Figure 4A). These data sug-
gest that IL-36-induced VEGF-A secretion from surround-
ing fibroblasts cell is capable of stimulating endothelial cell 
tubulogenesis.
Psoriasis Monocytes show increased 
adhesion
As monocyte recruitment is crucial for psoriasis lesion develop-
ment, but also comorbidities associated with psoriasis such as 
atherosclerosis, we decided to investigate the adhesive properties 
of psoriasis patients’ monocytes to HUVECs. To fully visualise 
potential differences in monocyte adhesion we worked with non-
stimulated HUVEC monolayers but also used the best described 
stimulus, TNFα, to reliably upregulate adhesion molecules on 
endothelial cells (54). Psoriasis and healthy monocytes (healthy 
n =  8, psoriasis n =  8) were allowed to adhere for 30  min to 
HUVECs. Psoriasis patients’ monocytes showed increased 
adherence to both untreated and TNFα activated HUVECs 
(Figures 5A,B).
FigUre 5 | Human umbilical vein endothelial cell monolayer was stimulated with or without TNFα 10 ng for 24 h. 1 × 105 monocytes were allowed to adhere to the 
monolayer for 30 min. Cells were visualised by immunofluorescence microscopy following CD14+ staining (b) and counted (a) (patient monocytes: psoriasis = 8; 
healthy = 8). Magnification 40×. Unpaired t-test *p < 0.05 and **p < 0.01.
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il-36γ-stimulated Macrophage 
supernatant activates endothelial cells
To further understand the functional role of IL-36γ beyond the 
epidermal compartment we examined the aspect of immune 
cell recruitment into the skin using endothelial cells and 
monocytes/macrophages. Supernatants from IL-36γ-stimulated 
macrophages were incubated with endothelial cells (HUVECs) 
for 24 h at a ratio of 1:10. As IL-36 alone has pro-inflammatory 
effects on HUVEC, a recombinant control was also added. 
IL-36γ-stimulated supernatant markedly increased expression 
of the adhesion molecule ICAM-1 (Figures 6A,B). Supernatant 
derived from IL-36γ-stimulated, psoriasis macrophages induced 
significantly more ICAM-1 expression when compared with 
healthy macrophages (Figures  6A,B). Stimulation of HUVECs 
with psoriasis macrophage supernatant resulted in increased 
adhesion of both healthy and psoriasis monocytes (Figure 6C) 
(healthy n = 8, psoriasis n = 8). However, regardless of HUVEC 
stimulation (untreated or treated, supernatant from healthy or 
psoriasis macrophages), psoriasis monocytes showed increased 
endothelial adhesion.
DiscUssiOn
IL-36γ is an IL-1 family cytokine with an increasingly recognised 
importance in the pathology of psoriasis (5). Various myeloid cells 
are thought to contribute to the pathology of psoriasis, including 
macrophages (33). Myeloid cells are capable of secreting IL-23 
and thus contributing to the IL-23/IL-17 axis, prominent in 
psoriasis (36). The central role of a type-3 immune response 
shift in psoriatic inflammation is convincingly demonstrated by 
the overwhelmingly positive therapeutic response of biologics 
interfering with the IL-23/IL-17 axis, which leads to complete 
or almost complete clearing of psoriatic symptoms in a large 
number of patients receiving these treatments. Within psoriasis 
lesions, monocytes, macrophages and dendritic cells all show 
positive staining for IL-23 (55).
With IL-36γ being released by keratinocytes, probably in the 
context of cellular stress/environmental challenges, its down-
stream actions on dermal cells including fibroblasts, endothelial 
cells but also resident and infiltrating myeloid cells such as mac-
rophages could represent a key step in both early and chronic lesion 
pathology. While IL-36γ has previously been shown to induce 
IL-23 mRNA in murine bone marrow derived dendritic cells, we 
here report secretion of IL-23 protein by human macrophages 
(56). Interestingly, other inflammatory cytokines prominent in 
psoriatic lesions, TNFα, IL-17, and IL-1, had little or no ability to 
induce IL-23 when compared with IL-36γ. Psoriasis macrophages 
secreted significantly more IL-23 following IL-36γ stimulation 
than healthy macrophages. Our findings also complement find-
ings from an imiquimod-induced mouse model of psoriasis which 
has shown to be dependent on MyD88 signalling in macrophages 
(57). Whilst macrophage derived IL-23 is thought to be crucial 
to the immunopathological development of psoriasis lesions, we 
are the first to report a viable cytokine agonist for this induction, 
in IL-36γ. Clinical case reports also support our findings and the 
idea of a potential IL-36-macrophage pathway within psoriasis 
pathology. Two case reports show patients with DITRA, who suf-
fer from a lack of function mutation in the endogenous IL-36RA, 
benefit from monocyte apheresis treatment (44, 58).
FigUre 6 | (a,b) Supernatants from IL-36γ-stimulated psoriasis or healthy macrophages were used to stimulate human umbilical vein endothelial cell (HUVECs) for 
24 h, and ICAM-1 (green) and DAPI (blue) expression as visualised by immunofluorescence microscopy is depicted in panel (a) and intensity of staining measured 
by fluorescence absorbance summarised in panel [(b); psoriasis n = 8, healthy n = 8]. (c) Healthy and psoriasis monocytes (1 × 105) were allowed to adhere to a 
HUVEC monolayer for 30 min. The monolayer was stimulated with supernatant derived from IL-36-stimulated/non-stimulated psoriasis or healthy derived 
macrophage supernatant. Patient monocytes: psoriasis n = 8, healthy n = 8. Unpaired t-test *p < 0.05 and **p < 0.01.
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IL-36γ induced secretion of IL-23 was enhanced when 
macrophages were primed and activated with IFNγ. IFNγ 
enhancement of/priming for IL-23 secretion from macrophages 
has previously also been shown with other TIR agonists such as 
TLRs (50, 59). IFNγ has also been shown to induce an inflam-
matory phenotype characteristic of psoriasis when injected into 
the skin and serum levels correlate with disease severity (60, 61). 
In this context it is noteworthy that IL-36, similar to other IL-1 
family members has been shown to enhance IFNγ production 
in CD4+ T cells (62, 63). We found in our experimental setting 
that synergy with IFNγ is a prominent feature for IL-36 induced 
responses but not for IL-17, TNFα, or the IL-1 family member 
and TIR agonist IL-1. Previous reports have also shown that IL-1 
induced TNFα secretion from macrophages is not enhanced by 
IFNγ (64).
TNFα was prominently induced in macrophages by IL-36γ. 
Similar to IL-23, psoriasis macrophages had higher basal 
expression levels and secreted significantly more TNFα when 
stimulated with IL-36γ. Consequently, IL-36γ induced TNFα 
from infiltrating macrophages would be well placed to potently 
stimulate the surrounding tissues to further orchestrate the 
immune response, activate the endothelium, and increase leuco-
cyte migration.
TNFα is known to be a prominent inflammatory activator of 
the endothelium and we show that IL-36 induced macrophage 
supernatant is a potent activator of the endothelium, with the 
adhesion molecule ICAM-1 showing upregulation (65). In 
accordance with enhanced cytokine secretion seen from psoriasis 
macrophages, their supernatant was able to achieve increased 
endothelial activation when compared with healthy supernatant. 
Deciphering the most important activator of the endothelium 
within the supernatant will require further study. Whilst, TNFα 
is a known activator of the endothelium and several biologic 
treatments targeting TNFα have proved successful in psoriasis 
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conditions (66), IL-36γ is known to induce other cytokines from 
macrophages (including a positive autocrine feedback on its own 
production) which could induce similar effects. The key infor-
mation from this set of experiments is the striking difference in 
the endothelium activating potential of IL-36-stimulated macro-
phages between healthy and psoriasis individuals. IL-36 is 
expressed in high abundance in all lesional psoriasis epidermis (5).
Enhanced cytokine secretion from psoriasis macrophages is 
characteristic of the exaggerated immune response associated 
with psoriasis (67). Previous studies have also shown psoriasis 
macrophages to secrete increased IL-8, IL-1α/β, and TNFα when 
untreated and this is in agreement with our findings (68, 69). 
Numerous genetic variations are thought to exist in psoriasis cells 
which lead to dysregulated immune responses (67). IL-36γ signals 
through NF-κB, and various variants—including TNFAIP3 (A20) 
and CARD14—are thought to exist within psoriasis cells that lead 
to increased activity of NF-κB (67, 70). Recent studies also sug-
gest IL-36 may play a role in macrophage polarisation (40), and 
thereby affect subsequent cytokine secretion. However, whether 
IL-36 has a direct or indirect role in macrophage polarisation 
within psoriasis is as yet unknown.
Whilst damaged keratinocytes may be a potential source of 
IL-36γ, macrophages within lesions also show positive IL-36 
staining (6). Interestingly, lung macrophages secrete IL-36γ in 
microparticles following LPS stimulation (71). Potential auto-
crine actions of IL-36 on macrophages thus require further study.
We report that following stimulation of endothelial cells 
with IL-36 induced macrophage supernatant, monocytes show 
significantly increased adherence. When compared with healthy 
controls, supernatants from psoriasis macrophages have an 
increased ability to stimulate and adhere to the endothelium 
(ICAM-1). Interestingly, regardless of the stimulus, psoriasis 
monocytes showed increased adhesion to both unstimulated 
and stimulated endothelial cells. A previous study has also found 
monocytes from psoriasis patients to show increased activation 
and integrin expression (72).
We report here that IL-36γ induced angiogenesis is dependent 
on VEGF-A induction. VEGF-A is perhaps the best documented 
inducer of angiogenesis, and its presence in psoriasis lesions is 
long established (73). VEGF-A and both VEGFRs are overex-
pressed in psoriasis lesions and serum levels of VEGF-A correlate 
with PASI (74–76). A genetic variant in VEGFA is also associated 
with more severe psoriasis (+405 CC) and is thought to result 
in increased VEGF-A production (29, 31). Interestingly, the 
same SNP is also associated with poor prognosis in patients with 
chronic heart failure (77). Importantly, it is thought that angio-
genesis precedes symptomatic lesion formation; so it could be 
hypothesised that IL-36γ released from damaged keratinocytes 
would be well placed to stimulate VEGF-A synthesis and thus 
angiogenesis when compared with other cytokines that would 
have importance in a chronic lesion (78).
Angiogenesis has even been muted as a potential therapeutic 
target for psoriasis (20, 79, 80). Case reports have demonstrated 
improvements in PASI through targeting pro-angiogenic factors 
such as VEGF-A. Bevacizumab, a monoclonal antibody against 
VEGF-A used in the treatment for solid cancers, has also been 
shown to be effective in treating psoriasis, including one case 
of complete remission for a patient being treated for metastatic 
colon cancer (81). Case reports for tyrosine kinase inhibitors 
that target VEGFRs such as sunitinib and sorafenib also have 
produced positive results regarding psoriasis symptom reduction 
(82–84). Of interest, G6-31, a murine antibody against VEGF-A 
has demonstrated therapeutic improvement, in a mouse model 
of psoriasis (85). VALPHA is a fusion protein that targets both 
TNFα and VEGF-A and has shown to be effective in treating TPA 
induced psoriasis in mouse models (86).
The findings presented here also may have implications for 
other inflammatory diseases. Crohn’s shares some immunologi-
cal aspects with psoriasis, namely the IL-23/IL-17 axis activation, 
and in addition, a potential role for IL-36 in Crohn’s is becoming 
apparent (6, 87). Interestingly, angiogenesis is also a feature of 
Crohn’s (88). Similarly, IL-36 has been implicated in mouse 
models of respiratory infection and again linked to the IL-23/
IL-17 axis, and furthermore, angiogenesis is associated with 
chronic lung inflammation (40, 89, 90). Whilst IL-36 is yet to be 
fully implicated in COPD, cigarette smoke, the causative agent of 
COPD, induces IL-36 from bronchial epithelial cells (91). COPD 
is heavily associated with Th17  cell driven inflammation (92). 
Psoriasis is emerging as a risk factor for COPD, and furthermore, 
mouse models of psoriasis show enhanced airway inflammation 
attributed to IL-23 signalling (93–95). For skin diseases there is 
emerging evidence for IL-36 to be upregulated in pathologies 
with neutrophil components (e.g., acne and hidradenitis sup-
purativa) and to some extent in all inflammatory diseases involv-
ing epidermal responses (96). Although, difficult to dissect the 
precise in vivo relevance of the IL-36-induced VEGF-A mediated 
angiogenesis, multiple observations point towards an important 
potential role. Angiogenesis does play a physiological important 
role in healing responses where IL-36 could have an important 
impact (97). In a mouse model of psoriasis, systemic anti-VEGF-A 
treatment has also reduced skin inflammation (85). However, 
VEGF-A is also induced by other skin inflammatory mediators 
such as TNFα, and the net effect of IL-36 remains to be shown in 
future in vivo studies.
Our data greatly support previous data suggesting a role for 
IL-36 in the pathology of psoriasis. IL-36 has been shown to be inti-
mately involved in the epidermal changes characterising psoriatic 
lesions. This study provides further evidence of a direct relation-
ship between the development of a Th17 psoriatic phenotype and 
IL-36. IL-36 acts on tissue infiltrating macrophage and actively 
promotes recruitment of monocytes which cumulatively amplify 
IL-23 expression, thus promoting polarisation of lymphocytes 
for increased IL-17/IL-22 expression. In addition, IL-36 directed 
angiogenesis is dependent on VEGF, a recognised precursor to the 
development of a psoriatic plaque. We therefore demonstrate a 
central, pivotal role of IL-36 in the development and propagation 
of psoriatic disease. This builds on current understanding of pso-
riasis pathogenesis and provides a further potential therapeutic 
target in managing disease. Given its potential role in establishing 
a psoriatic plaque this may offer an opportunity to affect the dis-
ease course through preventing a chronic disease signature being 
established. Thus, deciphering the exact significance of IL-36 in 
the psoriatic disease continuum remains an important issue for 
further translational and clinical studies.
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